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Abstract:		85	
Objective:	 Debate	 has	 focused	 on	 the	 effects	 of	 the	 selective	 serotonin	 reuptake	 inhibitor	86	 (SSRI)	antidepressants	on	heart	rate	(HR)	and	heart	rate	variability	(HRV),	both	of	which	are	87	 predictors	 of	 adverse	 cardiovascular	 events.	 Here	 we	 examine	 the	 associations	 between	88	 specific	 SSRI	antidepressants	 and	 resting	 state	HR	 (and	HRV)	after	accounting	 for	a	host	of	89	 potential	confounding	factors.		90	 	91	
Methods:	 Participants	 included	 10,466	 not	 taking	 antidepressants,	 46	 participants	 taking	92	 escitalopram,	 86	 taking	 citalopram,	 66	 taking	 fluoxetine,	 103	 taking	 paroxetine,	 and	 139	93	 taking	 sertraline.	 HR	 and	 HRV	 (RMSSD,	 HF)	 were	 extracted	 from	 10-minute	 resting-state	94	 electrocardiograms.	 Analyses	 including	 propensity	 score	 weighting	 and	 matching	 were	95	 conducted	using	R-statistics	to	control	for	potentially	confounding	variables.		96	 	97	
Results:	 Major	 findings	 indicated	 that	 users	 of	 all	 SSRI	 medications	 –	 except	 fluoxetine	 –	98	 displayed	 lower	HRV	 relative	 to	 non-users.	 Users	 of	 paroxetine	 also	 displayed	 significantly	99	 lower	HRV	relative	to	users	of	citalopram	(Cohen’s	d	=	0.42),	fluoxetine	(Cohen’s	d	=	0.54)	and	100	 sertraline	(Cohen’s	d	=	0.35),	but	not	escitalopram.	While	associations	were	also	observed	for	101	 HR	these	were	less	robust	than	those	for	HRV.	102	 	103	
Conclusions:	While	paroxetine	is	associated	with	decreases	in	HRV	relative	to	non-users,	as	104	 well	 as	 users	 of	 other	 SSRI	medications,	 fluoxetine	was	 the	 only	medication	 not	 to	 display	105	 significant	 alterations	 in	 HR	 or	 HRV.	 These	 conclusions	 are	 limited	 by	 the	 cross-sectional	106	 design	 and	 non-randomized	 nature	 of	 medication	 prescriptions.	 Findings	 highlight	 the	107	 importance	of	 focusing	on	 specific	medications,	 rather	 than	more	heterogeneous	 groupings	108	 according	to	antidepressant	action,	and	may	have	implications	for	health	and	wellbeing	over	109	 the	longer	term.	110	 	111	
Abbreviations:	analysis	of	covariance	(ANCOVA);	analysis	of	variance	(ANOVA);	Anatomical	112	 Therapeutic	Chemical	Classification	code	(ATC);	body	mass	index	(BMI);	Brazilian	113	 longitudinal	study	of	adult	health	(ELSA-Brasil);	Clinical	Interview	Schedule-Revised	(CIS-R);	114	 coronary	heart	disease	(CHD);	electrocardiogram	(ECG);	heart	rate	(HR);	heart	rate	variability	115	 (HRV);	high	frequency	power	(HF-HRV);	Minnesota	code	(MC);	propensity	score	matching	116	 (PSM);	propensity	score	weighting	(PSW);	root	mean	square	of	successive	squared	117	
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differences	(RMSSD);	serotonin	and	noradrenaline	reuptake	inhibitors	(SNRIs);	selective	118	 serotonin	reuptake	inhibitor	(SSRI);	tricyclic	antidepressants	(TCA’s)	119	120	
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Introduction	121	 Antidepressant	medications	 are	 a	 first-line	 treatment	 option	 for	moderate	 to	 severe	mood	122	 and	anxiety	disorders,	yet	some	studies	suggest	that	long-term	use	may	be	associated	with	an	123	 increased	 risk	 for	 cardiovascular	 disease	 [1-3].	 We	 recently	 reported	 that	 use	 of	 tricyclic	124	 antidepressants	 (TCA’s)	 is	 associated	 with	 a	 two-fold	 higher	 prevalence	 in	 coronary	 heart	125	 disease	(CHD),	relative	 to	non-use	 in	a	cross-sectional	analysis	on	the	Brazilian	 longitudinal	126	 study	of	adult	health	(ELSA-Brasil)	[4].	Although	no	associations	were	observed	for	the	SSRI	127	 class,	antidepressant	use	in	Brazil	is	lower	than	in	high-income	countries.	With	the	exception	128	 of	sertraline	and	fluoxetine,	SSRIs	are	not	freely	dispensed	in	public	health	pharmacies,	as	are	129	 tricyclics	 [5].	While	TCA’s	are	generally	not	recommended	 for	depressed	patients	who	have	130	 CHD	 [6],	 the	 effects	 of	 the	 selective	 serotonin	 reuptake	 inhibitor	 (SSRI)	 class	 of	131	 antidepressants	 remain	 unclear.	 In	 the	 present	 study,	 we	 examined	 the	 associations	 of	132	 specific	 medications	 in	 the	 SSRI	 class	 with	 resting	 state	 heart	 rate	 (HR)	 and	 heart	 rate	133	 variability	 (HRV),	 two	 psychophysiological	 indicators	 of	 health	 and	 wellbeing	 shown	 to	134	 predict	 future	 mortality	 [7].	 The	 heart	 is	 under	 tonic	 inhibitory	 control	 by	 the	135	 parasympathetic	(vagal)	nervous	system	when	at	rest	[8],	and	both	HR	and	HRV	under	resting	136	 conditions	may	 reflect	 vagally	mediated	 cardiac	 activity.	 It	 is	 noted	however,	 that	HRV	 is	 a	137	 more	specific	measure	of	vagal	activity	[9,	10],	while	HR	may	also	include	sympathetic	input.	138	 	139	 While	the	SSRIs	are	considered	to	be	the	safest	class	of	antidepressant	medications	for	use	in	140	 cardiac	patients	[e.g.	11],	they	have	also	been	reported	to	reduce	HRV	in	depressed	patients,	141	 compared	to	those	not	receiving	an	antidepressant,	and	to	normal	controls	[12].	A	variety	of	142	 mechanisms	have	been	proposed	to	contribute	to	the	development	of	cardiovascular	disease	143	 in	 users	 of	 antidepressants	 including	 SSRIs.	 These	 include	 increased	 HR,	 orthostatic	144	 hypotension,	 slowing	 of	 ventricular	 cardiac	 conduction,	 and	 antiarrhythmic	 activity	 [13].	145	 Another	strong	candidate	for	increased	risk	of	cardiovascular	disease	is	impairment	in	vagal	146	
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function	 [7].	 Vagal	 function	 plays	 an	 important	 regulatory	 role	 over	 a	 variety	 of	 allostatic	147	 systems	 [14]	 and	 investigation	 of	 the	 associations	 between	 SSRIs,	 HR	 and	 HRV	 have	148	 important	implications	for	the	physical	wellbeing	of	patients	who	use	these	medications	over	149	 the	long-term.		150	 	151	 Use	of	antidepressants	is	associated	with	impairment	in	vagally	mediated	cardiac	activity	[15]	152	 [see	 also	 16],	 associations	 that	 are	 most	 pronounced	 for	 the	 tricyclic	 antidepressants,	153	 followed	by	the	serotonin	and	noradrenaline	reuptake	 inhibitors	(SNRIs)	and	the	SSRIs.	We	154	 recently	observed	that	the	SSRIs	are	associated	with	a	small	decrease	in	heart	rate	and	HRV	155	 [15].	 Consistent	 effects	 had	 been	 reported	 in	 a	 prior	 study	 [16],	 with	 decreases	 in	 HR	156	 interpreted	 as	 a	 decrease	 in	 sympathetic	 activity	 and	 decreases	 in	 HRV	 reflecting	 parallel	157	 decreases	in	cardiac	vagal	effects.	SSRIs	may	interfere	with	the	activation	of	fast	Na+	channels	158	 consistent	with	class	I	anti-arrhythmic	agents,	and	calcium	current,	which	reflects	a	negative	159	 inotropic	effect	reducing	contractility	[17,	18].	The	HRV	reductions	associated	with	SSRI	use	160	 have	also	been	shown	to	be	at	least	partly	reversible,	suggesting	a	possible	causal	effect	[16].	161	 Although	adverse	effects	of	SSRIs	have	been	reported	[15,	16],	these	findings	contradict	other	162	 reports	of	increases	[19]	and	no	impact	[20]	on	HRV.	We	have	suggested	previously	[21]	that	163	 one	of	the	factors	underpinning	these	contradictory	findings	may	be	the	practice	of	grouping	164	 together	 heterogeneous	medications	within	 the	 SSRI	 class,	 leading	 to	 variable	 findings	 that	165	 depend	on	what	SSRI	medications	are	combined	in	a	particular	study.	For	instance,	paroxetine	166	 displays	 six	 times	 more	 antimuscarinic	 (anticholinergic)	 potency	 than	 sertraline	 [22],	167	 highlighting	the	heterogeneity	of	these	medications.	This	limitation	of	prior	studies	highlights	168	 the	 importance	of	 comparing	specific	medications	within	 the	SSRI	 class.	Other	explanations	169	 for	the	reported	contradictory	findings	are	that	studies	have	often	not	controlled	for	various	170	 confounding	 factors,	 which	may	 impact	 on	measures	 of	 vagal	 function.	When	 studies	 have	171	 controlled	 for	 these	 factors,	statistical	analyses	such	as	ANCOVA	have	often	been	employed,	172	
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which	 may	 lead	 to	 a	 phenomenon	 known	 as	 the	 “reversal	 paradox”	 –	 such	 that	 the	173	 relationship	between	two	variables	is	reversed,	diminished	or	enhanced	when	attempting	to	174	 statistically	control	for	a	third	variable	–	when	studies	do	not	randomly	allocate	participants	175	 to	group	[see	21	for	discussion].	This	makes	it	difficult	to	draw	conclusions	from	prior	studies	176	 that	have	employed	this	statistical	approach.	177	 	178	 For	the	first	time,	we	compare	multiple	medications	within	the	SSRI	class,	to	determine	and	179	 compare	the	impact	of	specific	SSRI	antidepressants	on	HR	and	HRV.	Some	of	the	limitations	180	 in	prior	 studies	were	addressed	using	 robust	 analytical	 techniques	 for	 controlling	potential	181	 confounding	factors.	This	approach	has	several	advantages	over	traditional	regression-based	182	 approaches,	 including	 improved	 control	 of	 confounding	 by	 not	 conflating	 propensity	 score	183	 methods	with	the	modelling	approach,	and	application	of	flexible	machine	learning	methods	184	 to	capture	complex	and	nonlinear	relationships	between	participant	grouping	and	potential	185	 confounding	variables	without	over-fitting	the	data	[23].	186	 	187	
Methods	188	
Participants	189	 ELSA-Brasil	 is	 a	 cohort	 of	 15,105	 civil	 servants	 aged	 35-74	 years	 enrolled	 between	August	190	 2008	and	December	2010	at	6	different	sites	 in	Brazil	(Belo	Horizonte,	Porto	Alegre,	Rio	de	191	 Janeiro,	Salvador,	Sao	Paulo	and	Vitoria).	The	study	design	and	sampling	procedures	of	ELSA-192	 Brasil	have	been	reported	previously	[24,	25].	Briefly,	eligible	participants	included	males	and	193	 females	 aged	 between	 35	 and	 74	 years	 who	 were	 active	 or	 retired	 employees	 of	 the	 six	194	 institutions.	 Exclusion	 criteria	 included	 severe	 cognitive	 or	 communication	 impairment,	195	 intention	 to	 quit	 working	 at	 the	 institution,	 and,	 if	 retired,	 residence	 outside	 the	196	 corresponding	 metropolitan	 area.	 Women	 with	 current	 or	 recent	 pregnancy	 were	197	 rescheduled	so	that	the	first	interview	could	take	place	4	months	after	delivery	of	their	child	198	
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[24].	The	ethics	committees	of	the	participating	universities	approved	the	research	protocol.	199	 All	participants	provided	written	informed	consent	after	a	complete	description	of	the	study.		200	 	201	 Here	 we	 report	 on	 a	 total	 of	 10,906	 participants	 after	 dropping	 participants	 on	202	 antidepressants	other	than	an	SSRI	(n=382	including	113	on	SNRIs,	174	on	TCA’s,	and	96	on	203	 other	antidepressants),	participants	on	whom	no	HRV	exam	was	available	(n=1813,	including	204	 504	 participants	 with	 ectopic	 beats),	 participants	 on	 whom	 ECGs	 were	 not	 available	 for	205	 scoring	 major	 Q	 wave	 abnormalities	 (n=1740),	 and	 participants	 missing	 data	 on	 other	206	 variables	 used	 in	 analysis	 (n=563).	 Included	 participants	 comprised	 non-users	 of	207	 antidepressant	 medications	 (controls,	 n=10,466),	 those	 taking	 escitalopram	 (n=46),	208	 citalopram	(n=86),	fluoxetine	(n=66),	paroxetine	(n=103)	and	sertraline	(n=139).	Participants	209	 on	fluvoxamine	were	not	included	in	the	present	study	due	to	small	numbers	of	participants	210	 taking	this	medication	(n=3).	211	 	212	
Procedures	213	 Participants	were	asked	to	abstain	from	caffeine,	alcohol	and	physical	activity	for	at	least	12	214	 hours	before	assessments.	Participants	were	asked	to	bring	all	of	the	prescription	and	over-215	 the-counter	pill	bottles	to	an	interview	for	review	by	the	interviewer.	Individuals	taking	one	216	 selective	 serotonin	 reuptake	 inhibitor	 (SSRI)	 medication	 continuously	 over	 the	 past	 two	217	 weeks	 were	 classified	 as	 users,	 and	 grouped	 according	 to	 the	 specific	 antidepressant	 they	218	 were	 taking.	 Selective	 serotonin	 reuptake	 inhibitors	 were	 defined	 using	 the	 Anatomical	219	 Therapeutic	 Chemical	 (ATC)	 Classification	 code:	 N06AB.	 A	 continuous,	 10-minute,	 resting-220	 state	ECG	was	also	obtained	from	participants	while	in	the	supine	position	from	which	HR	and	221	 HRV	were	extracted	using	standardised	methods.	[See	also:	26,	27].	The	electrocardiograms	222	 (ECGs)	were	 always	 collected	 in	 the	morning	 (8:00	 to	 12:00h)	 in	 a	 temperature-controlled	223	 room	 (21-24°C)	 and	were	 sampled	 at	 250	Hz	with	 a	 digital	 electrocardiograph	 (Micromed,	224	
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Brazil)	 consistent	 with	 Task	 Force	 recommendations.	 ECGs	 were	 processed	 blindly	 at	 a	225	 Central	 ECG	 Reading	 Center,	 where	 they	 were	 visually	 inspected	 for	 technical	 errors	 and	226	 inadequate	quality,	 and	 then	 stored	 for	 subsequent	analysis	 in	 a	Pyramis	ECG	management	227	 system	 (version	 6.2.b,	 Cardiac	 Science	 Corporation,	 Bothel,	 WA,	 USA).	 ECGs	 were	 codified	228	 electronically	using	the	Minnesota	code	manual	of	electrocardiographic	findings	by	validated	229	 software,	with	manual	over-reading	by	trained	cardiologists	to	ensure	quality	control.	Major	230	 Q	wave	abnormalities	were	determined	from	a	12-lead	ECG	as	defined	by	the	Minnesota	code	231	 (MC)	 scheme	 (MC	 1-1-X	 through	 to	 1-2-X).	 Dedicated	 software	 (Micromed	Wincardio	 4.4a,	232	 Brazil)	 automatically	 generated	 the	R-R	 interval	 series	 from	 the	 selected	ECG	 lead	with	 the	233	 highest	R-wave	amplitude	(usually	D2).	Data	were	then	processed	to	obtain	measures	of	HR	234	 and	HRV	including	the	root	mean	square	of	successive	squared	differences	(RMSSD)	and	high	235	 frequency	power	(HF-HRV).	RMSSD	and	HF-HRV	both	reflect	vagal	parasympathetic	activity	236	 and	 are	 usually	 highly	 correlated.	 HF-HRV	 (0.15–0.40	Hz)	was	 estimated	 and	 expressed	 in	237	 absolute	 units.	 Both	 RMSSD	 and	 HF-HRV	 were	 then	 log-transformed	 as	 a	 normalisation	238	 strategy.		239	 	240	
Covariates	241	 Covariates	 included	 sociodemographic	 factors	 (age;	 sex;	 level	 of	 education;	 race),	242	 cardiovascular	 risk	 factors	 (smoking;	 body	 mass	 index;	 hypertension;	 diabetes;	 and	243	 dyslipidemia),	 established	heart	disease	 and	associated	medications,	 physical	 inactivity	 and	244	 psychiatric	morbidity.	 Level	 of	 education	was	 entered	 as	 two	dummy	 coded	 variables	 (less	245	 than	 high	 school:	 yes	 versus	 no;	 completed	 high	 school:	 yes	 versus	 no),	 while	 race	 was	246	 entered	as	a	categorical	variable	indicating	whether	participants	were	non-White	(yes	versus	247	 no).	 Smoking	 status	 was	 indicated	 if	 participants	 were	 current	 smokers	 (current	 versus	248	 past/never)	 and	 body	 mass	 index	 (BMI)	 was	 determined	 as	 follows:	 weight	 in	 kilograms	249	 divided	by	height	 in	meters	squared.	Hypertension	was	defined	as	a	systolic	blood	pressure	250	
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≥140	mmHg,	a	diastolic	blood	pressure	≥90	mmHg,	or	use	of	antihypertensive	medications.	251	 Diabetes	was	 defined	 as	 self-reported	 or	 fasting	 blood	 glucose	 level	 ≥126	mg/dL,	 a	 2-hour	252	 oral	glucose	tolerance	test	glucose	level	≥200	mg/dL,	or	a	glycated	hemoglobin	level	≥6.5%.	253	 Dyslipidemia	was	 defined	 as	 an	 LDL	 cholesterol	 level	 ≥130	mg/dL	 or	 use	 of	 lipid-lowering	254	 medication.	Blood	samples	were	collected	after	a	12-hour	overnight	fast	and	medication	use	255	 was	determined	on	the	basis	of	pill	bottle	review.	Established	heart	disease	was	determined	256	 through	a	prior	history	of	a	physician-diagnosed	myocardial	infarction,	a	prior	percutaneous	257	 coronary	intervention	including	balloon	angioplasty	with	or	without	stent	placement,	a	prior	258	 surgical	 revascularization	consisting	of	 either	arterial	or	venous	grafts.	Complementing	 this	259	 self-report	information,	major	Q	wave	abnormalities	(yes	versus	no)	on	the	12-lead	ECG	were	260	 also	 entered	 into	 analyses	 as	 a	 covariate.	 Physical	 activity	 was	 measured	 using	 the	261	 International	Physical	Activity	Questionnaire	 [28]	 and	 categorized	according	 to	 low	activity	262	 versus	 moderate	 or	 high	 activity,	 as	 determined	 using	 scoring	 guidelines.	 Psychiatric	263	 morbidity	was	determined	by	trained	interviewers	using	the	Portuguese	version	[29]	of	 the	264	 Clinical	Interview	Schedule-Revised	(CIS-R)	[30].	The	CIS-R	version	was	applied	and	severity	265	 scores	were	obtained	ranging	from	zero	to	57.		266	 	267	
Statistical	Analysis	268	 Statistical	analysis	was	conducted	using	 IBM	SPSS	Statistics	Version	21	and	 the	R-statistical	269	 environment	 (version	 3.0.1).	 Participant	 characteristics	 were	 examined	 using	 one-way	270	 analyses	of	variance	(ANOVA)	for	contrasts	involving	continuous	dependent	measures,	and	χ2	271	 statistics	for	categorical	variables	(Table	1).	Tukey’s	HSD	is	reported	for	ANOVAs,	correcting	272	 for	multiple	comparisons,	while	standardised	residuals	(z-scores)	were	used	to	help	interpret	273	 χ2	statistics.	Our	main	 analyses	 involved	 comparison	of	 SSRI	 antidepressant	 users	 and	non-274	 users	on	HR,	RMSSD	and	HF-HRV,	before	and	after	application	of	propensity	score	techniques	275	 including	propensity	score	weighting	(PSW)	[23]	and	propensity	score	matching	(PSM)	[31]	276	
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to	 adjust	 findings	 for	 the	 above	 covariates.	 These	 techniques	 involve	 calculating	 a	 single	277	 propensity	 score	 on	 the	 basis	 of	 entered	 covariates	 for	 each	 participant	 that	 relates	 to	 the	278	 probability	 that	 the	 participant	 belongs	 to	 the	 same	 distribution	 (i.e.	 antidepressant	279	 grouping).	 Two	 propensity	 analytic	 methods	 were	 employed:	 PSW	 and	 PSM.	 While	 PSW	280	 involves	 entering	 the	 propensity	 score	 into	 regression	 models,	 PSM	 involves	 selecting	281	 comparison	participants	(non-users	of	antidepressants)	to	match	other	groups	on	propensity	282	 scores.	 PSW	 was	 carried	 out	 using	 the	 ‘twang’	 and	 ‘survey’	 packages,	 while	 PSM	 was	283	 conducted	 using	 the	 ‘MatchIt’	 package	 in	 the	 R	 statistical	 environment.	 Details	 on	 how	 to	284	 implement	these	procedures	have	been	described	previously	[23,	31].	PSM	was	conducted	as	285	 a	 sensitivity	 analysis,	 allowing	 the	 effective	 sample	 size	 of	 medication	 groupings	 to	 be	286	 increased	 and	potential	 Type	1	 error	 associated	with	discrepant	 sample	 sizes	 (i.e.	 between	287	 users	and	non-users	of	antidepressants)	in	PSW	to	be	avoided.	Effective	sample	sizes	reflect	288	 the	adverse	impact	of	increased	variance	on	precision	and	power	[23],	providing	an	estimate	289	 of	 the	number	of	 comparable	participants	 in	 each	group	after	 introducing	propensity	 score	290	 weights	 or	 dropping	 cases	 when	matching.	 Additional	 PSW	 analyses	 were	 conducted	 after	291	 dropping	control	participants	from	analysis.	This	analysis	allowed	the	effective	sample	size	of	292	 medication	groupings	to	be	increased,	achieving	a	higher-powered,	head-to-head	comparison	293	 between	SSRI	medications.	Cohen’s	d	effect	size	statistics	were	calculated	for	each	pair-wise	294	 comparison	with	values	of	0.2,	0.5,	 and	0.8	 interpreted	as	 small,	medium,	 and	 large	effects,	295	 respectively	 according	 Cohen’s	 guidelines	 [32,	 33].	 Effect	 sizes	 were	 calculated	 using	 an	296	 online	calculator	(available	here	at	The	Campbell	Collaboration:	http://goo.gl/zeLyuH)	[based	297	 on:	34].		298	 	299	
Results	300	
Participant	Characteristics	301	
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Descriptive	statistics	for	participants	are	reported	in	Table	1.	Participants	differed	on	age,	sex,	302	 education,	ethnicity,	LDL	cholesterol,	and	psychiatric	morbidity,	highlighting	the	importance	303	 of	propensity	score	techniques	to	better	control	for	the	associations	between	these	variables	304	 and	HR,	and	HRV.	It	is	possible	for	instance,	that	the	differences	in	confounding	variables	may	305	 account	 for	differences	between	groups	on	HR	and	HRV.	The	unadjusted	results	 for	HR	and	306	 HRV	are	also	reported	in	Table	1.	Findings	indicate	that	HR	is	reduced	in	users	of	citalopram,	307	 and	that	HRV	is	reduced	in	all	users	of	SSRIs	with	the	exception	of	those	on	fluoxetine.	In	the	308	 following	sections,	we	report	results	after	adjusting	for	potentially	confounding	variables	on	309	 the	basis	of	propensity	scores.	 It	 is	relevant	to	note	here	that	the	findings	for	 fluoxetine	did	310	 not	change	after	controlling	for	confounding	variables.	311	 	312	
Impact	of	SSRIs	on	Heart	Rate	and	HRV:	Propensity	Score	Analyses		313	 The	 differential	 impact	 of	 SSRIs	was	 determined	 following	 PSW	 and	 PSM.	 Effective	 sample	314	 sizes	 after	 PSW	 were	 as	 follows:	 controls,	 n=10,451;	 escitalopram,	 n=28;	 citalopram=28;	315	 fluoxetine=48;	paroxetine=62;	sertraline=61.	PSW	analyses	revealed	significant	alterations	in	316	 RMSSD	 (F(5,10900)=10.66,	 p<0.001)	 and	 HF-HRV	 (F(5,10900)=8.06,	 p<0.001),	 while	317	 alterations	were	observed	for	HR	at	trend	levels	(F(5,10900)=1.91,	p=0.089).	Effective	sample	318	 sizes	 after	 PSM	 were	 as	 follows:	 escitalopram,	 n=46;	 citalopram=86;	 fluoxetine=66;	319	 paroxetine=103;	 sertraline=139.	 Descriptive	 data,	 statistical	 tests	 and	 Cohen’s	d’	 effect	 size	320	 measures	are	summarised	in	Table	2.	The	major	finding	was	that	alterations	in	HR	and	HRV	321	 were	observed	for	all	users	of	SSRIs	except	for	fluoxetine	(light	grey	shaded	cells).	In	addition,	322	 users	of	paroxetine	displayed	robust	reductions	in	both	measures	of	HRV	(RMSSD,	HF-HRV)	323	 in	both	PSW	and	PSM,	relative	to	non-users,	findings	associated	with	small	to	moderate	effect	324	 size	(dark	grey	shaded	cells	in	Table	2).		325	 	326	
Specificity	Analyses	327	
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Additional	 PSW	 analysis	 was	 conducted	 to	 compare	 each	 SSRI	 medication	 after	 dropping	328	 controls	from	the	analyses.	This	allowed	for	the	effective	sample	size	of	medication	groupings	329	 to	 be	 increased	 and	 for	 a	 higher-powered,	 head-to-head	 comparison	 between	 SSRI	330	 medications	to	be	conducted.	After	application	of	PSW,	effective	sample	sizes	were	as	follows:	331	 escitalopram,	 n=36;	 citalopram=73;	 fluoxetine=57;	 paroxetine=84;	 sertraline=122.	 Analyses	332	 revealed	significant	differences	on	HR	(F(4,435)=2.52,	p=0.041)	and	RMSSD	(F(4,435)=2.99,	333	 p=0.019),	 but	 not	 HF-HRV	 (F(4,435)=1.48,	 p=0.21).	 Post	 hoc	 tests	 indicated	 that	 users	 of	334	 paroxetine	(MHR=67.48,	SE=1.12)	and	sertraline	(MHR=66.89,	SE=0.83)	displayed	significantly	335	 higher	HR	than	users	of	citalopram	(MHR=63.83,	SE=0.82)	(p=0.009,	Cohen’s	d=	0.43;	p=0.009,	336	 Cohen’s	 d=	 0.36).	 Users	 of	 paroxetine	 (MRMSSD=2.88,	 SE=0.05)	 also	 displayed	 significantly	337	 lower	 RMSSD	 than	 users	 of	 citalopram	 (MRMSSD=3.08,	 SE=0.06;	 p=0.019,	 Cohen’s	 d=	 0.42),	338	 fluoxetine	 (MRMSSD=3.14,	 SE=0.07;	 p=0.003,	 Cohen’s	 d	 =	 0.54)	 and	 sertraline	 (MRMSSD=3.06,	339	 SE=0.05;	p=0.011,	Cohen’s	d=	0.35).		340	 	341	
Discussion	342	 This	 study	 examined	 and	 compared	 the	 impact	 of	 specific	 antidepressants	within	 the	 SSRI	343	 class	on	resting-state	HR	and	HRV.	This	is	an	important	issue	as	chronic	alterations	of	HR	and	344	 HRV	by	SSRI	antidepressants	may	 lead	to	morbidity	 from	a	host	of	conditions	and	diseases,	345	 and	mortality	[7,	35].	Major	findings	from	this	study	suggest	that:	1)	all	users	of	SSRIs	–	except	346	 fluoxetine	–	display	alterations	in	HR	or	HRV	relative	to	non-users;	findings	for	HRV	appeared	347	 to	be	more	robust	and	consistent	for	HRV,	than	those	for	HR,	2)	users	of	citalopram	display	a	348	 mild	 bradycardia,	 characterised	 by	 reductions	 in	HR	 by	 up	 to	 4	 beats	 per	minute,	 findings	349	 associated	with	 a	 small	 to	moderate	 effect	 size,	 3)	 only	 users	 of	 paroxetine	 display	 robust	350	 reductions	in	both	measures	of	HRV,	findings	again	associated	with	a	small	to	moderate	effect	351	 size,	and	3)	users	of	paroxetine	also	display	small	to	moderate	reductions	on	HRV	relative	to	352	 users	of	citalopram,	fluoxetine	and	sertraline,	but	not	escitalopram.		353	
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	354	 These	associations	may	be	produced	through	a	variety	of	mechanisms	including	serotonergic	355	 receptors	in	brainstem	regions	involved	in	cardiovagal	control,	including	the	nucleus	tractus	356	 solitarius	 at	 which	 cardiorespiratory	 afferent	 fibres	 terminate,	 and	 the	 cardiac	 vagal	357	 preganglionic	 neurones	 and	 rostral	 ventrolateral	 medulla	 (the	 location	 of	 sympathetic	358	 premotor	neurones)	[36,	37].	While	different	receptors	appear	to	have	variable	effects,	5-HT1A	359	 and	 5-HT7	 contribute	 to	 mild	 bradycardia,	 a	 finding	 that	 was	 observed	 here	 for	 users	 of	360	 citalopram,	 who	 displayed	 a	 reduction	 in	 resting	 state	 HR	 by	 approximately	 ~4	 beats	 per	361	 minute.	 SSRIs	 may	 also	 inhibit	 cardiac	 and	 vascular	 Ca2+,	 Na+	 and	 K+	 channels	 further	362	 contributing	 to	mild	 bradycardia	 [17,	 18].	 In	 addition,	 the	 effect	 of	 paroxetine	may	 also	 be	363	 associated	 with	 anticholinergic	 effects	 [22],	 including	 inhibition	 of	 vagal	 efferent	 activity	364	 through	blockade	of	muscarinic	acetylcholine	receptors	at	the	sinoatrial	node.		365	 	366	 Large	 cohort	 studies	 and	 meta-analyses	 on	 the	 impact	 of	 SSRI	 medications	 have	 reported	367	 contradictory	findings	including	increases	[19],	decreases	[15,	16]	and	no	alterations	[20]	in	368	 HRV,	 leading	 to	much	 discussion	 in	 the	 literature	 [21,	 38,	 39].	 These	 reports	 highlight	 the	369	 need	 for	comparisons	between	different	antidepressant	medications	 from	the	SSRI	class,	an	370	 important	 contribution	 of	 the	 present	 study.	 Our	 findings	 extend	 our	 recent	 study	 on	 the	371	 impact	 of	 antidepressant	 class	 [15]	 to	 specific	 antidepressants	 within	 the	 SSRI	 class,	372	 demonstrating	 that	paroxetine	displays	 the	most	robust	reductions	 in	HRV	after	controlling	373	 for	 a	 number	 of	 confounding	 factors	 relative	 to	 controls,	 as	 well	 as	 users	 of	 other	 SSRI	374	 medications.	 These	 findings	 provide	 important	 new	 evidence	 for	 individual	 medications	375	 within	 the	 SSRI	 class,	 and	 highlight	 the	 need	 for	 further	 study	 in	 this	 area	 including	376	 investigation	of	 the	 long-term	effects	of	specific	antidepressants	within	the	SSRI	class	–	and	377	 paroxetine	 in	particular	–	on	physical	health	 and	 illness.	To	our	knowledge,	 this	 is	 the	 first	378	 comparison	of	multiple	medications	within	the	SSRI	class	on	measures	of	HR	and	HRV.		379	
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	380	 Paroxetine	 displayed	 the	most	 pronounced	 reductions	 in	 HRV,	 relative	 to	 both	 controls	 as	381	 well	as	users	of	other	medications,	with	the	exception	of	escitalopram.	Interestingly,	a	prior	382	 study	 on	 28	 inpatients	 with	 a	 DSM-IV	 diagnosed	 depressive	 episode	 also	 reported	 HRV	383	 reductions	when	paroxetine	was	prescribed	at	40mg	per	day	over	a	35	day	period	[40].	The	384	 authors	of	this	study	[40]	suggested	that	the	higher	dosage	of	paroxetine	may	impact	on	HRV	385	 in	 a	 similar	 way	 to	 tricyclic	 antidepressants.	 At	 higher	 concentrations	 (40	 mg	 /	 day	 and	386	 higher),	paroxetine	is	known	to	act	as	a	dual	serotonin/noradrenaline	reuptake	inhibitor	[41,	387	 42]	 and	 is	 characterised	 by	 appreciable	 antimuscarinic	 (anticholinergic)	 potency	 [41].	 It	 is	388	 interesting	 to	 note	 that	 our	 earlier	 study	 [15]	 reported	 that	 tricyclic	 antidepressants	 and	389	 SNRIs	 were	 associated	 with	 moderate	 to	 large	 increases	 in	 HR	 and	 decreases	 in	 HRV.	 By	390	 contrast,	paroxetine	in	the	present	study	is	associated	with	small	 to	moderate	reductions	 in	391	 HRV.	These	effect	sizes	are	presumably	smaller	than	those	we	observed	for	tricyclic	and	SNRI	392	 medications,	as	some	participants	on	paroxetine	may	have	been	prescribed	dosages	less	than	393	 40mg/day.	 It	 is	also	notable	that	while	SNRIs	and	tricyclic	antidepressants	may	also	 lead	to	394	 tachycardia	 in	 addition	 to	 reductions	 in	HRV,	users	of	paroxetine	 in	 the	present	 study	only	395	 exhibited	decreases	in	HRV,	not	increases	in	HR	(relative	to	non-users).			396	 	397	 In	contrast	to	paroxetine,	fluoxetine	was	the	only	antidepressant	that	was	not	associated	with	398	 significant	alterations	in	cardiac	activity.	Fluoxetine	is	generally	considered	a	safe	medication	399	 for	 patients	with	 cardiovascular	 disease.	 An	 early	 study	 [43]	 on	 depressed	 elderly	 patients	400	 with	pre-existing	cardiovascular	disease	reported	that	fluoxetine	decreased	HR	by	6%	(n=27),	401	 while	nortriptiline,	a	tricyclic	antidepressant,	was	associated	with	a	9%	increase	(n=52).	This	402	 study	 highlighted	 the	 contrasting	 effects	 of	 fluoxetine	 versus	 nortriptiline	 on	 HR,	 with	 the	403	 authors	concluding	that	increases	in	HR	may	reflect	an	increase	in	cardiac	work,	which	over	404	 time	 may	 have	 clinically	 adverse	 effects.	 The	 only	 medication	 associated	 with	 robust	405	
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decreases	 in	HR	 in	 the	present	study	was	citalopram	(PSW	Cohen’s	d:	0.35;	PSM	Cohen’s	d:	406	 0.49).		407	 	408	 Although	 fluoxetine	 has	 been	 a	 popular	 pharmacological	 treatment	 for	 mood	 and	 anxiety	409	 disorders,	 recent	 systematic	 reviews	 indicate	 that	 other	 medications	 (e.g.	 sertraline,	410	 escitalopram)	may	be	more	efficacious	[44].	In	fact,	sertraline	is	the	most	commonly	studied	411	 SSRI	medication	in	depressed	patients	with	cardiovascular	disease	and	is	considered	to	be	the	412	 first	 line	 drug	 of	 choice	 in	 this	 patient	 population	 [45].	 In	 the	 present	 study,	 sertraline	413	 displayed	 some	 alterations	 of	 cardiac	 activity	 relative	 to	 non-users,	 however	 PSW	 findings	414	 were	not	confirmed	using	PSM.	We	have	recently	reported	[46]	that	chronic	treatment	with	415	 sertraline	 (50-mg/d)	 does	 not	 impact	 on	HRV	 over	 a	 period	 of	 6-weeks	 in	 an	 independent	416	 cohort	of	patients	with	major	depressive	disorder.		417	 	418	 Escitalopram	also	displayed	alterations	of	cardiac	activity,	 including	moderate	reductions	 in	419	 RMSSD	 in	both	PSW	and	PSM.	Escitalopram	was	also	 the	only	SSRI	medication	 that	did	not	420	 significantly	 differ	 from	 paroxetine	 in	 a	 direct	 comparison	 across	multiple	 antidepressants	421	 highlighting	 the	 potentially	 adverse	 chronic	 effects	 of	 this	 medication	 on	 HRV.	 Recall	 that	422	 these	findings	were	observed	in	users	taking	this	medication	continuously	over	the	past	two	423	 weeks.	 In	 contrast	 to	 these	 results,	 we	 have	 previously	 reported	 that	 a	 single	 dose	 of	424	 escitalopram	 (20mg),	 relative	 to	 placebo,	 is	 associated	 with	 increases	 in	 HF-HRV,	 findings	425	 associated	with	a	moderate	to	large	effect	size	[47].	It	is	possible	therefore	that	acute	versus	426	 chronic	administration	of	escitalopram	 leads	 to	different	effects	on	HRV.	Others	have	noted	427	 that	 chronic	 administration	 of	 SSRIs	 may	 lead	 to	 significant	 inhibition	 of	 various	428	 cardiovascular	ion	channels	leading	to	certain	pro-	or	arrhythmic	effects	[17,	18].		429	 	430	
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It	 is	 important	 to	 acknowledge	 here	 a	 variety	 of	 limitations	 associated	 with	 our	 study	431	 including	 a	 lack	 of	 additional	 information	 on	 participant’s	 use	 of	 antidepressants	 including	432	 dose	and	length	of	use.	It	is	possible	for	instance	that	the	findings	observed	here	are	less	than	433	 what	might	be	observed	for	participants	on	higher	dosage	(e.g.	paroxetine	at	dosages	higher	434	 than	40mg	/	day)	and	extended	use	(e.g.	years).	While	sensitivity	analyses	confirmed	findings	435	 for	paroxetine	(robust	reductions	 in	HRV)	and	fluoxetine	(no	significant	associations	for	HR	436	 or	HRV),	it	is	possible	that	factors	including	dosage	and	length	of	use	may	have	contributed	to	437	 the	findings	that	could	not	be	confirmed	using	sensitivity	analyses	especially	HRV	reductions	438	 for	 other	 medications	 including	 escitalopram,	 citalopram	 and	 sertraline.	 It	 is	 important	439	 however,	to	place	these	limitations	in	the	context	of	various	strengths	of	our	study,	including	440	 a	comparison	of	multiple	medications	 from	the	SSRI	class	on	HR	and	HRV	 for	 the	 first	 time	441	 and	use	of	propensity	score	techniques	to	better	control	for	potentially	confounding	factors.		442	 	443	 In	 summary,	 users	 of	 all	 SSRI	 medications	 –	 with	 the	 exception	 of	 fluoxetine	 –	 display	444	 alterations	 in	 cardiac	 activity,	 relative	 to	 non-users.	 Critically,	 users	 of	 paroxetine	 even	445	 display	reductions	 in	HRV	relative	to	users	of	other	SSRI	medications,	with	the	exception	of	446	 escitalopram.	These	findings	may	have	important	clinical	implications.	First,	HRV	in	particular	447	 reflects	 the	 functioning	 of	 the	 vagus	 nerve	 [48]	 and	 its	 impairment	 may	 lead	 to	 impaired	448	 regulation	 over	 various	 allostatic	 systems	 [14,	 49],	 which	 may	 have	 adverse	 impacts	 on	449	 physical	 health	 in	 those	 patients	 who	 use	 these	 medications	 over	 the	 long-term.	 Second,	450	 patients	with	mood	and	anxiety	disorders	already	display	alterations	in	HR	and	HRV	[15,	46,	451	 50,	 51]	 and	 further	 reductions	 may	 have	 further	 consequences	 for	 patient	 health.	 Third,	452	 clinicians	 should	 be	 particularly	 mindful	 of	 physical	 health	 in	 patients	 treated	 with	453	 paroxetine,	and	also,	possibly	escitalopram,	which	are	associated	with	the	greatest	impacts	on	454	 HRV.	Future	research	on	the	long-term	effects	of	SSRI	antidepressants,	and	the	possibility	that	455	 simple	changes	in	health	behaviours	may	ameliorate	these	associations,	is	needed.	456	
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Table	1:	Participant	characteristics	(unadjusted)	including	means	(M)	and	standard	errors	(SE)	for	continuous	variables	and	number	of	participants	(n)	and	percentage	of	participants	relative	to	sample	size	of	sub-group	(%).	
	 Controls	
(n=10,466)	
Escitalopram	
(n=46)	
Citalopram	
(n=86)	
Fluoxetine	
(n=66)	
Paroxetine	
(n=103)	
Sertraline	
(n=139)	
p-value	
Age,	M	(SE)	 52.10	(0.09)	 54.48	(1.37)	 55.95	(1.02)*	 53.86	(1.18)	 53.63	(0.92)	 52.60	(0.76)	 p<0.001	
Females,	n	(%)	 5,515	(52.7)	 32	(69.6)	 67	(77.9)*	 55	(83.3)*	 78	(75.7)*	 115	(82.7)*	 p<0.001	
Education,	n	(%)	
		Less	than	High	School	
		High	School	
	1386	(13.2)	3620	(34.6)	 	0*		4	(8.7)	*	 	3	(3.5)*	31	(36.0)	 	8	(12.1)	25	(37.9)	 	5	(4.9)*	26	(25.2)	 	14	(10.1)	40	(28.8)	 	p=0.001	p=0.001	
Ethnicity,	n	(%)	
		Non-White	
	5,154	(49.2)	 	15	(32.6)	 	28	(32.6)	*	 	22	(33.3)	 	37	(35.9)	 	48	(34.5)	*	 	p<0.001	
Current	Smokers,	n	(%)	 1,330	(12.7)	 6	(13.0)	 9	(10.5)	 12	(18.2)	 16	(15.5)	 14	(10.1)	 p=0.58	
Body	Mass	Index,	M	
(SE)		
27.03	(0.05)		 27.27	(0.78)		 26.60	(0.51)	 27.31	(0.55)	 25.98	(0.42)		 27.67	(0.42)	 p=0.11		
Hypertension,	n	(%)	 3,773	(36.1)	 16	(34.8)	 32	(37.2)	 21	(31.8)	 34	(33.0)	 55	(39.6)	 p=0.88	
Diabetes,	n	(%)	 2,063	(19.7)	 7	(15.2)	 13	(15.1)	 9	(13.6)	 12	(11.7)	 31	(22.3)	 p=0.16	
Dyslipidemia,	n	(%)	 5,985	(57.2)	 33	(71.7)	 60	(69.8)	 44	(66.7)	 73	(70.9)	 101	(72.7)	*	 p<0.001	
Hard	CHD,	n	(%)	 474	(4.5)	 2	(4.3)	 1	(1.2)	 1	(1.5)	 9	(8.7)	 7	(5.0)	 p=0.16	
Major	Q-Waves,	n	(%)	 263	(2.5)	 1	(2.2)	 1	(1.2)	 0	 2	(1.9)	 3	(2.2)	 p=0.77	
Physical	Inactivity,	n	
(%)	
8,037	(76.8)	 40	(87.0)	 61	(70.9)	 52	(78.8)	 80	(77.7)	 114	(82.0)	 p=0.25	
CIS-R	Total	Score2,	M	
(SE)	
7.87	(0.08)	 9.15	(1.08)	 12.26	(1.03)*	 10.12	(1.10)	 11.29	(1.04)*	 14.33	(0.83)*	 p<0.001	
Heart	Rate,	M	(SE)	 66.78	(0.09)	 65.55	(1.19)	 63.72	(0.80)*	 65.64	(0.94)	 66.53	(0.95)	 67.02	(0.77)	 p=0.041	
RMSSD,	M	(SE)	 3.23	(0.01)	 2.98	(0.08)*	 3.08	(0.06)	 3.17	(0.07)	 2.94	(0.05)	*	 3.09	(0.05)	*	 p<0.001	
HF-HRV,	M	(SE)	 5.36	(0.01)	 4.83	(0.18)	*	 4.97	(0.12)	*	 5.19	(0.13)	 4.84	(0.11)	*	 5.12	(0.11)	 p<0.001	1	CIS-R	Total	Score:	Severity	of	psychiatric	morbidity	determined	using	Clinical	Interview	Schedule-Revised.	2	*Refers	 to	one-way	ANOVA	 in	which	each	group	 is	 compared	 to	 controls	 (Tukey’s	HSD,	p<0.05)	or	 standardized	 residuals	 (z-scores)	from	χ2	statistics	 lying	outside	±	1.96	reflecting	a	 significance	value	of	p	<	0.05	using	Fisher's	exact	 test	with	 the	Monte	Carlo	when	necessary						
 Table 2. Effects of multiple selective serotonin reuptake inhibitors (SSRIs) on heart rate and heart rate variability using propensity score 
weighting (PSW) and propensity score matching (PSM).  	 																								
Notes: 1 PSM was conducted to confirm findings from PSW to enhance effective sample size and combat potential for Type 1 error resulting from unequal sample sizes in PSW. Paroxetine was the only 
antidepressant to display robust reductions in both measures of HRV (RMSSD, HF-HRV) in both PSW and PSM, relative to non-users, findings associated with small to moderate effect size (dark grey coloured 
cells). Fluoxetine did not show any alterations in heart rate or HRV relative to non-users on either analysis (light grey coloured cells). 2 Values for non-users from those individuals matched to citalopram. As 
bipartite matching was used, and control participants were matched to each antidepressant group, values differ for each comparison. For brevity the values for non-users matched to other antidepressant 
groupings are not shown here. Note however, that the Cohen’s d effect size measure for each comparison was calculated using the values from controls that were matched to the users of the particular 
Propensity Score Weighting (using ‘twang’ and ‘survey’ packages) 
 Non-users (n=10,451) Escitalopram (n=28) Citalopram (n=28) Fluoxetine (n=48) Paroxetine (n=62) Sertraline (n=61) 
 M  SE M  SE Cohen’s d PSW p M  SE Cohen’s d PSW p M  SE Cohen’s d PSW p3 M  SE Cohen’s d PSW p4 M  SE Cohen’s d PSW p 
HR 66.81 0.09 66.50 1.77 -0.03 0.005 63.55 1.58 -0.35 <0.001 64.75 0.93 -0.22 0.68 67.25 1.16 0.05 <0.001 66.12 1.15 -0.08 0.034 
RMSSD 3.23 0.01 2.98 0.09 -0.24 0.001 2.98 0.08 -0.24 0.001 3.20 0.07 -0.03 0.60 2.89 0.06 -0.33 <0.001 3.08 0.07 -0.10 0.041 
HF-HRV 5.36 0.01 4.91  0.17 -0.44 0.009 4.78 0.17 -0.57 0.001 5.28 0.15 -0.08 0.60 4.78 0.18 -0.57 <0.001 5.03 0.16 -0.32 0.041 
Propensity Score Matching (using MatchIt package)1 
 Non-users (matched)2 Escitalopram (n=46) Citalopram (n=86) Fluoxetine (n=66) Paroxetine (n=103) Sertraline (n=139) 
 M  SE M  SE Cohen’s d PSM p M  SE Cohen’s d PSM p M  SE Cohen’s d PSM p3 M  SE Cohen’s d PSM p4 M  SE Cohen’s d PSM p 
HR 67.75 0.99 65.55 1.19 -0.07 0.74 63.72 0.80 -0.49 0.002 65.64 0.94 -0.30 0.09 66.53 0.95 -0.03 0.84 67.02 0.77 -0.23 0.054 
RMSSD 3.15 0.05 2.98 0.08 -0.46 0.038 3.08 0.06 -0.14 0.42 3.17 0.07 0.11 0.55 2.94 0.05 -0.50 <0.001 3.09 0.05 -0.19 0.12 
HF-HRV 5.16 0.12 4.82 0.18 -0.34 0.11 4.97 0.12 -0.17 0.28 5.19 0.14 0.04 0.82 4.84 0.11 -0.34 0.018 5.12 0.11 -0.16 0.17 
antidepressant being compared. 3 Light grey shaded cells reflect correspond to p-values for fluoxetine, the only antidepressant not associated with alterations in HR and HRV. 4 Dark grey shaded cells reflect 
findings for users of paroxetine in which robust reductions in both measures of HRV (RMSSD, HF-HRV) on both PSW and PSM were observed, relative to non-users, findings associated with small to moderate 
effect size. 
